Journal of Cancer Research and Clinical Practice

Journal of Cancer Research and Clinical Practice (JCRCP) is an International Peer-reviewed Double-Blind Open Access Journal that aims to promote present clinical research on oncology that may play a significant role in the prevention and cure of large families of Cancer and updates recent studies related to Clinical practice of Cancer Science, Cancer Surgery and Therapy.

JCRCP Deals With Research Pertaining To Different Types Of Cancer Such As Prostate Cancer, Bladder Cancer, Bone Cancer, Blood Cancer, Brain Cancer, Cervical Cancer, Ovarian Cancer, Breast Cancer, Renal Cancer, Endocrine Cancer, HPV-Associated Cancer, Head And Neck Cancer, Oral Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Skin Cancer, Lung Cancer, and Esophageal Cancer.

Pubtexto Journal Of Cancer Research And Clinical Practice Devoted To The Publication Of Papers In The Field Of Cancer Research Includes Cancer Science, Cancer Surgery & Therapy, Types Of Cancer, Diagnostic Biomarkers, Malignant Progression, Drug Sensitivity And Resistance, Resistance To Treatment, Novel Methods, Chemotherapy, Radiation Therapy, Etc.

Pubtexto Journal of Cancer Research and Clinical Practice has dealt with an ideal editorial board comprised of acclaimed scientists from across the globe. Each article is subjected to a rigorous peer review. The journal maintains the highest standards in terms of quality and originality. In addition to Research Articles, the Journal also publishes high-quality Perspectives, Commentaries, and Reviews to ensure healthy debates among its readers, describing original research in the fields of basic, translational and clinical cancer research.

Journal of Cancer Research and Clinical Practice (JCRCP) follows a rapid review process and welcomes the direct submission of articles from global authors. 

Submit your manuscript online portal

Plagiarism Policy

The articles submitted by authors must contain a minimum of 80% unique content (Which should be unique and must not copy from any other websites). The authors must maintain 100% uniqueness in the text’s results and conclusion. We will resend the articles, which have below 80% uniqueness to the authors for revision and asked for resubmissions with uniqueness (as per guidelines).

Benefits to authors

We provide many author benefits, such as free PDFs, a liberal copyright policy, social media, and social media optimization that improve citations and help readers h potential collaborators, and correspondents with a platform to publish their research work and update the recent advances.

Review Process: Double-blinded peer review process

Journal of Cancer Research and Clinical Practice (JCRCP) is an International Peer-reviewed Double-Blind Open Access Journal that aims to promote present clinical research on oncology that may play a significant role in the prevention and cure of large families of Cancer and updates recent studies related to the Clinical Practice of Cancer Science Cancer Surgery and Therapy.

Translational Therapeutics

Translational Therapeutics is dedicated to scientific work that has possible direct applicability in clinical uses or opens new avenues for treatments. The type of manuscript ranges from basic research to early informative clinical trials with extensive concomitant biomaterial analyses. Translational concepts include new computational or wet lab Technologies as well.

Molecular Diagnostics

The Molecular Diagnostic subject category considers studies that examine genomic, transcriptomic, epigenomic, and proteomic biomarkers in the context of cancer diagnosis, staging, prognosis, therapeutic prediction, and radiographic and pathologic characteristics. We are particularly interested in papers that explore novel or evolving biomarkers with direct clinical applicability in cancer care.

Genetics and Genomics

This subject category covers the use of genetic epidemiology and bioinformatics, together with molecular and cell biology, to identify and characterize the genetic and epigenetic factors underlying tumor development and progression. We are interested in papers that focus on the mechanistic consequences of genetic variance, and adequately powered studies of how genetic and epigenetic variation impacts patient risk and outcome phenotypes, in particular where these point to new clinical approaches. Wherever possible, bioinformatics analyses should be supported by experimental results.

Cellular and Molecular Biology

The Cellular and Molecular Biology subject category considers studies that provide novel insight into basic cellular and molecular mechanisms of cancer, but are not biomarker, methodology, or pathology focused. Studies considered for this category will generally go beyond in vitro and/or in silico evaluation of basic cellular and molecular mechanisms of cancer, and usually include the use of appropriate in vivo model systems. Findings of studies considered for this category should be clinically and/or therapeutically applicable.

Epidemiology

The Epidemiology subject category focuses on prevention, early detection, and factors that influence the risk and prognosis of cancer.